Yahoo
NYSE - Nasdaq Real Time Price USD

Thermo Fisher Scientific Inc. (TMO)

708.29 +4.14 (+0.59%)
As of 11:36:52 AM EDT. Market Open.
Trade TMO on Coinbase
Chart Range Bar
Loading chart for TMO

What's happening with TMO?

19m ago
Powered by Yahoo Scout

Thermo Fisher Scientific’s latest coverage combines reported third-quarter 2026 sales of $12.1 billionwith exposure to several expanding genomics and cell-and-gene-therapy markets. The articles also highlight valuation tension, with independent commentary describing limited upside at recent levels while market reports point to long-term demand opportunities.

Powered by Yahoo Scout
  • Previous Close 704.15
  • Open 703.58
  • Bid 706.58 x 4000
  • Ask 706.87 x 8000
  • Day's Range 699.90 - 709.25
  • 52 Week Range 435.27 - 710.84
  • Volume 473,400
  • Avg. Volume 2,102,850
  • Market Cap (intraday) 261.888B
  • Beta (5Y Monthly) 0.88
  • PE Ratio (TTM) 37.36
  • EPS (TTM) 18.96
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield 1.88 (0.27%)
  • 1y Target Est 750.92
  • Morningstar Rating Rating available with Stock Picks access

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services internationally. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. The Life Sciences Solutions segment includes reagents, instruments, and consumables for biological and medical research; discovery and production of drugs and vaccines; and diagnosis of infections and diseases. Its Analytical Instruments segment provides instruments, consumables, software, and services for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The Specialty Diagnostics segment offers clinical diagnostics products, such as liquid ready-to-use and lyophilized immunodiagnostic reagent kits, calibrators, controls, protein detection assays, and instruments; immunodiagnostic offerings comprising developing, manufacturing, and marketing of complete blood-test systems for the clinical diagnosis and monitoring of allergy, asthma and autoimmune diseases; microbiology offerings, such as dehydrated and prepared culture media, collection and transport systems, instrumentation and consumables to detect pathogens in blood, diagnostic and rapid direct specimen tests, quality-control products, and associated products; transplant diagnostics products, including human leukocyte antigen typing and testing for the organ transplant market; and healthcare market channel offerings. Its Laboratory Products and Biopharma Services segment provides laboratory products, research and safety market channel, and pharma services and clinical research. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts.

www.thermofisher.com

125,000

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/29/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

TMO
22.57%
S&P 500 (^GSPC)
12.86%

1-Year Return

TMO
27.31%
S&P 500 (^GSPC)
12.12%

3-Year Return

TMO
65.77%
S&P 500 (^GSPC)
87.64%

5-Year Return

TMO
13.49%
S&P 500 (^GSPC)
67.75%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 12.14B
Earnings 1.72B
Profit Margin 14.18%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
2B
4B
6B
8B
10B
12B
14.5%
15.0%
15.5%
16.0%

Analyst Insights

View More

Analyst Price Targets

560.00 Low
750.92 Average
708.29 Current
830.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/23/2026
Analyst Citigroup
Rating Action Maintains
Rating Buy
Price Action Raises
Price Target 685 -> 800

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    14.94%

  • Return on Assets (ttm)

    5.23%

  • Return on Equity (ttm)

    13.38%

  • Revenue (ttm)

    47.35B

  • Net Income Avi to Common (ttm)

    7.07B

  • Diluted EPS (ttm)

    18.96

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    6.06B

  • Total Debt/Equity (mrq)

    75.36%

  • Levered Free Cash Flow (ttm)

    6.45B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: